Multiple sclerosis (MS) is an autoimmune disease affecting the central nervous system. The immune system attacks the nerves, which causes communication problems between the brain and rest of the body. Immunosuppressant and immunomodulators, along with physiotherapy, are widely used to treat MS.
Market leaders operating in the market have undertaken various organic growth strategies in the multiple sclerosis therapeutics market. The multiple sclerosis therapeutics market players include Merck & Co., Inc.; Novartis AG; Bayer AG; Sanofi; Bristol-Myers Squibb Company; Horizon Therapeutics plc.; Teva Pharmaceutical Industries Ltd; Takeda Pharmaceutical Company Limited; F. Hoffmann-La Roche Ltd.; and Biogen. The companies have been implementing various strategies that have helped the growth of the company and brought about various changes in the market. The companies have utilized organic strategies, such as launches, expansion, and product approvals. Moreover, the companies have utilized inorganic strategies, including mergers & acquisitions, partnership, and collaborations.
Biogen, Novartis AG, and Merck & Co., Inc. – Notable Market Players in Multiple Sclerosis Therapeutics Market
Below is the list of the growth strategies done by the players operating in the multiple sclerosis therapeutics market:
|
Year |
News |
|
March 2019 |
Merck received USFDA approval for MAVENCLAD (cladribine) tablets as first and only short-course oral treatment for relapsing-remitting and active secondary progressive multiple sclerosis. |
|
March 2020 |
Bristol Myers Squibb announced that Zeposia (ozanimod) has been approved by the FDA for the treatment of adults with relapsed multiple sclerosis, an autoimmune disease in which the body’s immune system attacks the protective myelin sheaths that cover its nerves. |
|
August 2020 |
Horizon Therapeutics plc. received US FDA approval for Kesimpta (ofatumumab) for the treatment of relapsing forms of multiple sclerosis in adults. |
